https://signalnewslima.com/press-releases/81741/uk-financial-ltd-launches-maya-chain-and-begins-digital-asset-migration/ 2026-10-24T11:48:25+00:00 https://signalnewslima.com/press-releases/81742/flightcompensations-launches-managed-claims-service-for-passengers-affected-by-flight-disruptions-2/ 2026-10-24T11:48:26+00:00 https://signalnewslima.com/press-releases/81743/taiwan-brings-herbal-heritage-and-modern-innovation-to-supplyside-global-2026/ 2026-10-24T11:48:26+00:00 https://signalnewslima.com/press-releases/81744/likang-life-sciences-showcases-personalized-cancer-immunotherapy-and-global-ambitions-at-abu-dhabi-future-health-summit-2026/ 2026-10-24T11:48:26+00:00 https://signalnewslima.com/press-releases/81745/genmab-and-incyte-announce-clinical-trial-collaboration-in-metastatic-colorectal-cancer/ 2026-10-24T11:48:26+00:00 https://signalnewslima.com/press-releases/81746/incyte-and-genmab-announce-clinical-trial-collaboration-in-metastatic-colorectal-cancer/ 2026-10-24T11:48:26+00:00 https://signalnewslima.com/press-releases/81747/bull-investors-have-opportunity-to-lead-webull-corporation-securities-fraud-lawsuit-filed-by-the-rosen-law-firm-3/ 2026-10-24T12:04:24+00:00 https://signalnewslima.com/press-releases/81748/deep-robotics-unveils-five-research-advances-in-embodied-ai/ 2026-10-24T12:36:21+00:00 https://signalnewslima.com/story/81749/ukraine-reports-restoration-of-starlink-access-after-temporary-limits/ 2026-10-24T12:36:22+00:00 https://signalnewslima.com/press-releases/81750/voka-3d-anatomy-pathology-app-surpasses-1-million-registrations-worldwide/ 2026-10-24T12:36:22+00:00 https://signalnewslima.com/press-releases/81751/bioinvents-bi-1808-and-keytrudar-induce-durable-responses-in-heavily-pretreated-platinum-resistant-ovarian-cancer/ 2026-10-24T12:36:22+00:00 https://signalnewslima.com/press-releases/81752/semtech-brings-5g-network-slicing-fips-140-3-to-iacp-2026/ 2026-10-24T12:52:29+00:00 https://signalnewslima.com/press-releases/81753/parabilis-medicines-presents-updated-phase-1-2-data-for-zolucatetide-demonstrating-compelling-efficacy-and-favorable-safety-and-tolerability-profile-in-patients-with-desmoid-tumors/ 2026-10-24T12:52:29+00:00